Literature DB >> 6847674

Allosteric interactions among drug binding sites on calmodulin.

J D Johnson.   

Abstract

Felodipine is a fluorescent dihydropyridine Ca2+-antagonist. It binds to calmodulin in a Ca2+-dependent manner, and undergoes a fluorescence increase which allows us to monitor its interaction with calmodulin. Hydrophobic ligands including the calmodulin antagonist, R24571 and Ca2+ antagonists, prenylamine and diltiazem, bind to calmodulin and potentiate felodipine binding by as much as 20 fold. These studies suggest that allosteric interactions occur among different drug binding sites on calmodulin. Our results are discussed in terms of the mechanism of action of calmodulin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6847674     DOI: 10.1016/0006-291x(83)91530-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  A calmodulin-like ca receptor in the ca channel.

Authors:  J D Johnson
Journal:  Biophys J       Date:  1984-01       Impact factor: 4.033

2.  Interaction of smooth muscle relaxant drugs with calmodulin and cyclic nucleotide phosphodiesterase.

Authors:  S Ronca-Testoni; S Hrelia; G Hakim; C A Rossi
Journal:  Experientia       Date:  1985-01-15

3.  High-affinity formation of a 2:1 complex between gramicidin S and calmodulin.

Authors:  J A Cox; M Milos; M Comte
Journal:  Biochem J       Date:  1987-09-01       Impact factor: 3.857

4.  Loss of conformational stability in calmodulin upon methionine oxidation.

Authors:  J Gao; D H Yin; Y Yao; H Sun; Z Qin; C Schöneich; T D Williams; T C Squier
Journal:  Biophys J       Date:  1998-03       Impact factor: 4.033

5.  Protein kinase C inhibition by calmodulin and its fragments.

Authors:  H Krüger; W Schröder; K Buchner; F Hucho
Journal:  J Protein Chem       Date:  1990-08

6.  Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells.

Authors:  A Ramu; R Spanier; H Rahamimoff; Z Fuks
Journal:  Br J Cancer       Date:  1984-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.